Humana Inc. ($HUM) Stock Forecast: Down 9.2% Today

What is Humana Inc.?

Humana Inc. (HUM) is a leading health insurance company providing a wide range of healthcare services, including Medicare Advantage plans, Medicaid, and ACA coverage. The company has been closely monitoring policy changes and market trends to maintain its competitive edge in the healthcare sector.

Why is Humana Inc. going down?

HUM stock is down 9.2% on Jan 28, 2026 19:10

• Humana's stock experienced a significant 21.13% decline following the Centers for Medicare & Medicaid Services' unexpected announcement of a minimal 0.09% increase in Medicare Advantage payments for 2027.
• The lower-than-anticipated funding raised concerns about profit margins not only for Humana but also for other industry players like CVS Health and UnitedHealth Group.
• The soft outlook for fiscal year 2026, coupled with concerns over proposed payment rates and declining memberships in Medicare Advantage and Medicaid, contributed to investor unease and the bearish movement in Humana's stock.
• As Humana navigates these regulatory challenges and adjusts its cost structures, investors are eagerly awaiting the company's upcoming conference call to gain insights into its earnings performance and short-term outlook amidst the evolving healthcare landscape.

HUM Price Chart

HUM Technical Analysis

HUM News

Elevance making difficult decisions amid healthcare minefield

Elevance Health reported a significant profit increase in Q4 2025 despite rising costs but faces challenges in Medicaid, Medicare, and ACA markets. The company plans a year of "execution and repositioning" to strengthen performance and align cost structures. Elevance is adjusting pricing, refining products, and selectively investing to return to profit targets amidst policy-driven changes and increased medical cost trends.

https://insurancenewsnet.com/innarticle/elevance-making-difficult-decisions-amid-healthcare-minefield

Humana (HUM) Falls 21% on Medicare Payment Update

Humana Inc. (NYSE:HUM) stock fell 21.13% after the Centers for Medicare & Medicaid Services (CMS) announced a much lower-than-expected 0.09% increase in Medicare Advantage payments for 2027. This flat funding, instead of the anticipated 4-6% growth, raised concerns about profit margins for Humana and other insurance companies like CVS Health and UnitedHealth Group. Humana is scheduled to hold a conference call on February 11, 2026, to discuss its fourth-quarter and full-year 2025 earnings and provide a short-term outlook following these policy updates.

https://sg.finance.yahoo.com/news/humana-hum-falls-21-medicare-153142370.html

US Health Insurer Elevance Health Issues Soft Outlook, Lower Premium Forecast For 2026

Elevance Health (NYSE:ELV) reported mixed Q4 2025 earnings with revenues below consensus but adjusted EPS beating estimates. The health insurer also issued a soft outlook for fiscal year 2026, forecasting lower premium growth and a decline in Medicare Advantage and Medicaid memberships. Concerns were also raised regarding the Centers for Medicare & Medicaid Services' proposed payment rates for 2027, which do not align with current medical cost trends.

https://www.benzinga.com/markets/earnings/26/01/50192293/us-health-insurer-elevance-health-issues-soft-outlook-lower-premium-forecast-for-2026

Centene (CNC) Loses 10% on Flat Medicare Funding

Centene Corp. (NYSE:CNC) saw a 10.26 percent drop in its stock price after the Centers for Medicare and Medicaid Services (CMS) announced nearly flat funding for Medicare Advantage in 2027, projecting only a 0.09 percent increase in net average payment. This decision, along with proposed tighter risk-adjustment rules, negatively impacted several listed insurers, including Centene, which is heavily reliant on government-sponsored programs. Investors are now awaiting Centene's Q4 and full-year 2025 earnings release on February 6, 2026, and the company's future outlook.

https://finviz.com/news/290184/centene-cnc-loses-10-on-flat-medicare-funding

Elevance Health (ELV) Deep-Dive: Navigating the 2026 Regulatory Storm and the Carelon Transformation

Elevance Health (ELV) is facing a critical period in 2026 due to regulatory pressures, particularly concerning Medicaid and Medicare Advantage, and increased medical costs. Despite its transformation into a diversified health services company with its Carelon brand driving growth, the company released conservative 2026 EPS guidance, causing investor concern. Investors are closely watching for stabilization in the Medical Loss Ratio and potential Medicaid rate adjustments to signal a turnaround for the long-term compounding potential of the stock.

https://markets.financialcontent.com/stocks/article/finterra-2026-1-28-elevance-health-elv-deep-dive-navigating-the-2026-regulatory-storm-and-the-carelon-transformation

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 6.4% Today

ZCash ($ZEC) Crypto Forecast: Down 12.9% Today

Monero ($XMR) Crypto Forecast: Down 7.9% Today

Ethereum ($ETH) Crypto Forecast: Down 5.8% Today

XRP ($XRP) Crypto Forecast: Down 11.1% Today

Tezos ($XTZ) Crypto Forecast: Down 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.1% Today

Cardano ($ADA) Crypto Forecast: Down 6.3% Today

Silver ($XAG) Commodity Forecast: Down 13.5% Today

Stox ($STX) Crypto Forecast: Down 5.7% Today

Humana Inc. Price History

02.00.2026 - HUM Stock was up 2.8%

• A significant investment in Humana by Ninety One UK Ltd, combined with adjustments in holdings by other institutional investors, likely enhanced investor confidence in the company's future.
• Humana's strong quarterly earnings and dividend announcement reinforced the bullish trend, indicating strong financial performance and growth potential.
• Despite concerns about risks associated with Medicare Advantage and reimbursement pressures, Humana's attractive core business model in U.S. seniors' healthcare was evident through surpassing Q3 earnings expectations and maintaining a "Hold" consensus analyst rating.
• Operational changes at UnitedHealth Group due to external audits and cybersecurity issues with the BlackCat ransomware gang may have indirectly influenced investor sentiment, potentially leading them to view Humana as a more stable investment option in the healthcare industry.

15.00.2026 - HUM Stock was up 2.8%

• The renewed partnership between Graves Gilbert Clinic and Humana, ensuring in-network care for Humana-insured patients in south-central Kentucky, likely boosted investor confidence in Humana's growth prospects and market presence.
• Humana's strategic move to sell two office buildings in San Antonio's Medical Center area as part of its real estate optimization strategy could be seen as a positive step towards cost reduction and operational efficiency, potentially contributing to the bullish market movement.
• The acquisition of a new position in Humana by Pacific Capital Partners Ltd, following the company's strong Q3 earnings report and revenue growth, might have further fueled investor optimism and contributed to the stock's upward trajectory.
• Overall, these developments, along with the broader positive sentiment in the healthcare insurance sector, could have played a significant role in driving the bullish movement in Humana's stock today.

27.00.2026 - HUM Stock was down 21.2%

• Humana's stock experienced a strong bearish movement today, dropping over 13% in premarket trading.
• The bearish trend was primarily driven by the Trump administration's proposal of a minimal 0.09% increase in Medicare Advantage payment rates for 2027, significantly below expectations.
• This proposal has raised concerns among analysts and investors about potential benefit reductions or plan exits by insurers like Humana, impacting the company's stock performance.
• The market reaction reflects the heavy reliance of Humana on Medicare Advantage plans and the regulatory uncertainty surrounding future payment rates, leading to a significant sell-off of the stock.

27.00.2026 - HUM Stock was down 20.2%

• The bearish movement in HUM stock today could be attributed to the overall negative sentiment in the health insurance sector, as indicated by the declines in industry peers like UnitedHealth (UNH) and CVS Health (CVS).
• UnitedHealth's reported drop in quarterly earnings and projected revenue decline for 2026, along with plans to reduce Medicare Advantage benefits, likely raised concerns about rising medical costs across the sector, impacting companies like Humana.
• The administration's proposal for near-flat Medicare Advantage rates and a House Judiciary antitrust probe into pharmacy practices also added to the negative market sentiment, leading to the bearish movement in HUM stock.
• Despite recent positive analyst upgrades for Elevance Health (ELV), the broader challenges and uncertainties in the health insurance industry seem to have overshadowed any potential positive developments, contributing to the downward trend in Humana's stock price.

27.00.2026 - HUM Stock was down 19.7%

• Humana and other health insurers like UnitedHealth Group saw declines due to the proposal of flat rates for Medicare Advantage in 2027, surprising investors and leading to a negative market sentiment.
• Lowering the price target for CVS Health amidst concerns over Medicare Advantage rates and a House probe into pharmacy-hub practices may have added to the overall bearish sentiment in the healthcare sector.
• The pre-market trading session showed Humana lagging behind, indicating a continuation of the downward trend influenced by the proposed Medicare reimbursement rates.
• The unexpected news of flat reimbursement rates and the broader political and legal landscape facing health insurers like Humana and UnitedHealth Group contributed to the bearish movement in the stock market today.

27.00.2026 - HUM Stock was down 19.2%

• Humana's share value dropped by more than 20% as a result of the latest proposal by the Trump administration to keep Medicare Advantage payment rates almost stagnant for 2027, a stark contrast to the anticipated 4-6% increase.
• This unforeseen regulatory adjustment not only had repercussions for Humana but also led to a widespread sell-off in the health insurance sector, affecting major players like UnitedHealth Group and CVS Health. This reaction signaled apprehensions regarding narrower profit margins and regulatory ambiguity.
• Despite Humana's strong financial position marked by substantial revenue growth and favorable valuation metrics, the market strongly responded to the regulatory change, introducing substantial uncertainty regarding the company's future earnings.
• The overall market sentiment towards health insurers dependent on Medicare Advantage schemes took a negative turn, resulting in a significant drop in Humana's stock price and underlining the sector's susceptibility to regulatory modifications and governmental policies.

16.11.2025 - HUM Stock was down 5.1%

• Humana's stock dropped after announcing the retirement of its current insurance president and the appointment of a former Amazon executive to the role. This leadership change may have caused uncertainty among investors, leading to the bearish market movement.
• The reaffirmation of annual guidance by Humana, despite falling short of consensus estimates for earnings per share, could have further contributed to the negative sentiment among investors.
• The lack of commentary on the 2026 open-enrollment period may have also added to investor concerns about the company's future profitability, prompting the bearish trend in the stock price.

28.00.2026 - HUM Stock was down 9.2%

• Humana's stock experienced a significant 21.13% decline following the Centers for Medicare & Medicaid Services' unexpected announcement of a minimal 0.09% increase in Medicare Advantage payments for 2027.
• The lower-than-anticipated funding raised concerns about profit margins not only for Humana but also for other industry players like CVS Health and UnitedHealth Group.
• The soft outlook for fiscal year 2026, coupled with concerns over proposed payment rates and declining memberships in Medicare Advantage and Medicaid, contributed to investor unease and the bearish movement in Humana's stock.
• As Humana navigates these regulatory challenges and adjusts its cost structures, investors are eagerly awaiting the company's upcoming conference call to gain insights into its earnings performance and short-term outlook amidst the evolving healthcare landscape.

28.00.2026 - HUM Stock was down 7.0%

• Humana Inc. saw a notable decline in its stock price today due to concerns about its Medicare Advantage and Medicaid memberships, compounded by the risk of losing a key contract with The Queen’s Health Systems.
• The company's stock was further affected by the negative sentiment prevailing in the healthcare sector following the announcement of stable funding for Medicare Advantage in 2027 by the Centers for Medicare and Medicaid Services, impacting several insurers like Humana.
• Investor confidence in Humana may have been weakened by regulatory pressures, decreasing reimbursements, and potential care disruptions highlighted by the contract dispute with The Queen’s Health Systems.
• The market movement possibly reflects the uncertainty surrounding Humana's future prospects as investors await updates on its financial performance and strategic plans in a changing healthcare environment.

28.00.2026 - HUM Stock was down 5.7%

• Current concerns about Humana losing a significant contract with Queen’s Health Systems are contributing to the bearish movement in its stock today, potentially impacting 11,000 Medicare Advantage patients and creating uncertainty about its future revenue streams.
• The overall decline in the healthcare sector, influenced by the Centers for Medicare and Medicaid Services' proposed minimal increase in Medicare Advantage payments for 2027, is putting additional pressure on Humana's stock price.
• Despite being considered undervalued by some analysts, the negative investor sentiment towards Humana is influenced by uncertainties related to its contractual disputes and market conditions.
• Michael Burry's recent investment in Molina Healthcare during the insurer's turmoil underscores a changing landscape in the healthcare industry. Companies like Molina, focusing on Medicaid, may offer more stability compared to Medicare-focused insurers like Humana.

11.11.2025 - HUM Stock was up 5.4%

• Institutional investors, including State Street Corp, are increasing their holdings in Humana, indicating growing confidence in the company's future prospects, which is contributing to the bullish movement in the stock.
• CVS Health recently announced a strategic plan that emphasizes technology-driven growth and higher-margin segments, positively impacting the healthcare sector and potentially boosting investor sentiment towards companies like Humana.
• Humana's dedication to community impact through funding non-profit organizations in Oklahoma is in alignment with its values and enhances its reputation, attracting socially responsible investors.
• California Public Employees Retirement System and Federated Hermes Inc. have increased their stake in Humana, reinforcing the positive outlook on the company. Analysts maintain a "Hold" rating but with a target price indicating potential growth ahead.

11.11.2025 - HUM Stock was up 5.1%

• The bullish movement in Humana Inc. ($HUM) stock today can be attributed to the increased holdings by institutional investors like State Street Corp and California Public Employees Retirement System, indicating confidence in the company's growth prospects and financial performance.
• The announcement of Humana Healthy Horizons in Oklahoma funding six nonprofits with $295,500 showcases the company's commitment to addressing critical health-related social needs, which may have positively influenced investor sentiment.
• Analysts maintaining a "Hold" rating on Humana with a consensus target price of $296.84 suggests a stable outlook for the stock, supported by the company's strategic initiatives and dividend payouts.
• Overall, the positive market movement of Humana Inc. ($HUM) today reflects investor optimism fueled by institutional investments, community impact initiatives, and steady growth projections in the healthcare sector.